All Stories

  1. Distribution, severity, and management of joint pain in patients with acromegaly
  2. Adult survivors of sickle cell disease, transfusion-dependent beta-thalassaemia and childhood acute leukaemia in England: protocol for a mixed methods data linkage and health-related quality of life survey study
  3. Mineralocorticoid effects of fludrocortisone and hydrocortisone in primary adrenal insufficiency: EU-AIR patient data
  4. Cardiovascular safety of testosterone therapy—Insights from the TRAVERSE trial and beyond: A position statement of the European Expert Panel for Testosterone Research
  5. Conservatively managed non-functioning pituitary macroadenomas—cohort study from the UK Non-functioning Pituitary Adenoma Consortium
  6. Metabolic syndrome in childhood, adolescent, and young adult cancer survivors: recommendations for surveillance from the International Late Effects of Childhood Cancer Guideline Harmonization Group
  7. The Cost of Adrenal Insufficiency in England—Analysis of NHS HES Data
  8. APPROACH: Analysis of Proton versus Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health – study protocol paper for a phase III multicentre, open-label randomised controlled trial
  9. Risk of diabetes in childhood and young adult cancer survivors
  10. Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality?
  11. Safety and Effectiveness of a Biosimilar Recombinant Growth Hormone in Adults with Growth Hormone Deficiency: Analysis of Final Data from PATRO Adults, an International Post-Marketing Surveillance Study
  12. Symptoms and steroid dose adjustments following the Covid-19 vaccine in patients with adrenal insufficiency
  13. The impact of radiotherapy on the hypothalamo-pituitary axis: old vs new radiotherapy techniques
  14. Natural history of non-functioning pituitary microadenomas: results from the UK non-functioning pituitary adenoma consortium
  15. A study of acromegaly-associated headache with somatostatin analgesia
  16. Oral Octreotide Capsules and Paltusotine in Management of Acromegaly
  17. Rivaroxaban: A Rare Cause of Spontaneous Bilateral Adrenal Haematomas
  18. Paltusotine, a novel oral somatostatin receptor ligand in the management of acromegaly
  19. Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance
  20. Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis
  21. Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childhood Cancer Survivors
  22. Adjuvant Rituximab – exploratory trial in young people with Graves’ disease
  23. Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
  24. ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises
  25. Outcomes of 756 patients with differentiated thyroid cancer and excellent response to treatment: An evidence‐based paradigm for long‐term surveillance strategies
  26. Post-operative volumes following endoscopic surgery for non-functioning pituitary macroadenomas are predictive of further intervention, but not endocrine outcomes
  27. Characterization of patients with adrenal insufficiency and frequent adrenal crises
  28. Evaluation of cardiovascular risk factors in long-term survivors of adult- and childhood-onset brain tumours: a pilot study
  29. Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults)
  30. Interpretation of the endocrinology of hospital inpatients
  31. The severity of obstructive sleep apnoea does not
  32. Safety of current recombinant human growth hormone treatments for adults with growth hormone deficiency and unmet needs
  33. Management of persistent acromegaly following primary therapy: The current landscape in the UK
  34. Performance of the unilateral AV/IVC index in primary hyperaldosteronism subtype prediction: A validation study in a single tertiary centre
  35. Prothrombotic fibrin network characteristics in patients with acromegaly: a novel mechanism for vascular complications
  36. Construction of a predictive scoring system as a guide to screening and confirmation of the diagnosis of primary aldosteronism
  37. Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from the PATRO Adults study
  38. No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study
  39. Outcomes of Patients with Nelson’s Syndrome after Primary Treatment: A Multicenter Study from 13 UK Pituitary Centers
  40. Is Chemotherapy Implicated in the Development of Hypopituitarism in Childhood Cancer Survivors?
  41. When Can We Discharge Differentiated Thyroid Cancer Patients Who Present With High-Risk Disease and Subsequently Have an Excellent Response to Treatment?
  42. Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study
  43. Can We Discharge Dynamically Risk-Stratified Low-Risk (Excellent Response to Treatment) Thyroid Cancer Patients After 5 Years of Follow-Up?
  44. Hypothalamo‐pituitary axis irradiation dose thresholds for development of hypopituitarism in adult‐onset gliomas
  45. Glucocorticoid management of adrenal insufficiency in the United Kingdom: assessment using real-world data
  46. Management of glucocorticoids following adrenalectomy for ACTH-independent Cushing's syndrome
  47. Mortality data from the European Adrenal Insufficiency Registry-Patient characterization and associations
  48. Late-onset X-linked adrenal hypoplasia (DAX-1, NR0B1): two new adult-onset cases from a single center
  49. Endemic goitre and hypothyroidism in an adult female patient dependent on total parenteral nutrition
  50. Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study
  51. In Response to: Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely than Other Glucocorticoids
  52. Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour
  53. Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity - data from the EU-AIR
  54. Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency
  55. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline
  56. Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours
  57. Response to ‘How we define hyponatremia?’
  58. The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure
  59. The diagnosis and management of inpatient hyponatraemia and SIADH
  60. Endocrine sequelae beyond 10 years in survivors of medulloblastoma
  61. The effects of pituitary and thyroid disorders on haemostasis: potential clinical implications
  62. Lanreotide autogel in acromegaly – a decade on
  63. European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy
  64. Atypical Presentation of Riedel’s Thyroiditis: Multifocal Nodular Fibrosis and Resolution with Levothyroxine
  65. Serum vascular endothelial growth factor (VEGF) is elevated in GH deficient adults
  66. Partial Growth Hormone Deficiency is Associated With an Adverse Cardiovascular Risk Profile and Increased Carotid Intima-Medial Thickness.
  67. Current therapy and drug pipeline for the treatment of patients with acromegaly
  68. GH sensitivity of GH-deficient adults is dependent on gender but not timing of onset
  69. Hypogonadotropic hypogonadism: a consequence of Chiari-I malformation
  70. A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly
  71. Resolution of secondary amenorrhoea following withdrawal of dihydocodeine
  72. The Diagnosis of Partial Growth Hormone Deficiency in Adults with a Putative Insult to the Hypothalamo-Pituitary Axis
  73. The Impact of Short-Term Fasting on the Dynamics of 24-Hour Growth Hormone (GH) Secretion in Patients with Severe Radiation-Induced GH Deficiency
  74. A Densitometric and Morphometric Analysis of the Skeleton in Adults with Varying Degrees of Growth Hormone Deficiency
  75. Quality of Life in Adult Growth Hormone Deficiency
  76. The Phenotype of Adults with Partial Growth Hormone Deficiency
  77. Insulin sensitivity is impaired in adults with varying degrees of GH deficiency
  78. Impact of Growth Hormone Status on Body Composition and the Skeleton
  79. Central and peripheral actions of somatostatin on the growth hormone–IGF-I axis
  80. The Novel Somatostatin Ligand (SOM230) Regulates Human and Rat Anterior Pituitary Hormone Secretion
  81. Growth Hormone Replacement Decreases Plasma Levels of Matrix Metalloproteinases (2 and 9) and Vascular Endothelial Growth Factor in Growth Hormone-Deficient Individuals
  82. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status
  83. Adults with Partial Growth Hormone Deficiency Have an Adverse Body Composition
  84. Low Bone Mass Is an Infrequent Feature of the Adult Growth Hormone Deficiency Syndrome in Middle-Age Adults and the Elderly
  85. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis
  86. Adult growth hormone replacement: current understanding
  87. Plasma total homocysteine concentrations in adults with growth hormone (GH) deficiency: effects of GH replacement
  88. Adult Growth Hormone Replacement: Lessons Learned and Future Direction
  89. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults
  90. Timing of onset of growth hormone deficiency is a major influence on insulin-like growth factor I status in adult life
  91. Lipoprotein lipase gene variants relate to presence and degree of microalbuminuria in Type II diabetes
  92. Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome
  93. Spinal irradiation impairs the osteo-anabolic effects of low-dose GH replacement in adults with childhood-onset GH deficiency
  94. Differential Effects of GH Replacement on the Components of the Leptin System in GH-Deficient Individuals
  95. GH-Deficient Survivors of Childhood Cancer: GH Replacement during Adult Life
  96. The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients
  97. Survivors of child-hood cancer: long-term endocrine and metabolic problems dwarf the growth disturbance.
  98. Growth hormone: current and future therapeutic applications
  99. Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency
  100. Clinical presentation of PCOS following development of an insulinoma: Case Report
  101. Survivors of childhood cancer: long-term edocrine and metabolic problems dwarf the growth distrubance
  102. Influences on quality of life in GH deficient adults and their effect on response to treatment
  103. Gonadotrophin-releasing hormone analogues: a novel treatment for premenstrual asthma
  104. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults